Capital Impact Advisors’s Allogene Therapeutics ALLO Stock Holding History

Capital Impact Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,076	Closed	-$129K	–	176
2023 Q1	$129K	Buy	26,076 +9,175	+54%	+$58.8K	0.16%	166
2022 Q4	$106K	Sell	16,901 -2,638	-14%	-$24.4K	0.1%	220
2022 Q3	$196K	Buy	19,539 +3,839	+24%	+$52.2K	0.2%	183
2022 Q2	$179K	Buy	+15,700	New	+$139K	0.17%	205
2021 Q1	–	Sell	-41,800	Closed	-$1.05M	–	110
2020 Q4	$1.05M	Sell	41,800 -85,396	-67%	-$2.78M	0.26%	98
2020 Q3	$4.8M	Buy	127,196 +90,000	+242%	+$3.39M	1.42%	14
2020 Q2	$1.59M	Sell	37,196 -41,336	-53%	-$1.49M	0.53%	88
2020 Q1	$1.53M	Buy	78,532 +3,114	+4%	+$74.2K	0.64%	74
2019 Q4	$1.96M	Hold	75,418	–	–	0.69%	83
2019 Q3	$2.06M	Buy	75,418 +10,756	+17%	+$306K	0.78%	50
2019 Q2	$1.72M	Buy	+64,662	New	+$1.8M	0.63%	87

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital Impact Advisors's ALLO Position: Q2 2023 in Review

Capital Impact Advisors sold out of Allogene Therapeutics (ALLO) in Q2 2023, closing a stake of 26,076 shares — an estimated $129K sold.

Capital Impact Advisors first reported a position in ALLO in Q2 2019 and held it in 11 quarters. The position peaked at $4.8M in Q3 2020. 171 funds tracked by Wall St. Rank hold ALLO as of Q2 2023.

Capital Impact Advisors reported no remaining Allogene Therapeutics position as of Q2 2023 after selling out during the quarter.
Capital Impact Advisors sold 26,076 Allogene Therapeutics shares in Q2 2023, an estimated $129K.
Capital Impact Advisors first reported a position in Allogene Therapeutics in Q2 2019 and held it in 11 quarters.
Capital Impact Advisors's Allogene Therapeutics position peaked at $4.8M in Q3 2020.
171 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2023.

Based on Capital Impact Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.